Polymeric antigen BLSOmp31 formulated with class B CpG-ODN in a nanostructure (BLSOmp31/CpG-ODN/Coa-ASC16) administered by parenteral or mucosal routes confers protection against Brucella ovis in Balb/c mice. (March 2021)

• Record Type: Journal Article
• Authors: Moran, María Celeste; Bence, Angel Ricardo; Vallecillo, María Fernanda Sánchez; Lützelschwab, Claudia María; Rodriguez, Marcelo Gastón; Pardo, Romina; Goldbaum, Fernando Alberto; Zylberman, Vanesa; Palma, Santiago Daniel; Maletto, Belkys Angélica; Estein, Silvia Marcela
• Is Part Of: Research in veterinary science. Volume 135(2021)
• Page Start: 217
• Page End: 227
• Publication Date: 2021-03
• Subjects: BLSOmp31/CpG-ODN/Coa-ASC16 -- Experimental vaccine -- Immune response -- Brucella ovis -- Protection -- Murine model; Veterinary medicine -- Periodicals; Veterinary Medicine -- Periodicals; Médecine vétérinaire -- Périodiques; Médecine vétérinaire -- Recherche -- Périodiques; Diergeneeskunde; 636.089
• DOI: 10.1016/j.rvsc.2021.02.011
• Languages: English
• ISSNs: 0034-5288

Abstract

Abstract: Previously, we demonstrated that the chimera BLSOmp31 formulated in chitosan microspheres or Poloxamer407-Chitosan administered via the nasal and the ocular mucosa conferred partial protection in sheep against B. ovis . In this work, we tested a new delivery system for mucosal immunization with BLSOmp31 in the murine model to improve the efficacy of previously used formulations. First, we evaluated the protective efficacy against B. ovis induced by BLSOmp31 administered by the subcutaneous route using either BLSOmp31 alone, co-administered with immunostimulatory synthetic oligodeoxynucleotides containing unmethylated cytosine-guanine motifs (CpG-ODN) or with CpG-ODN in a nanostructure called Coa-ASC16 compared with BLSOmp31 emulsified in Incomplete Freund Adjuvant. Then, we evaluated the protection conferred by the best performing formulation (BLSOmp31/CpG-ODN/Coa-ASC16) administered by both subcutaneous and ocular routes. BLSOmp31/CpG-ODN/Coa-ASC16 injected subcutaneously did not induce higher IgG antibody levels compared to BLSOmp31 alone or BLSOmp31/CpG-ODN but it did stimulate a mixed immune Th1-Th2 response with the highest levels of IFN-ɣ and conferred significant protection against the B. ovis challenge. Although ocular instillation of BLSOmp31/CpG-ODN/Coa-ASC16 showed a similar degree of protection compared to the parenteral route (3.66 and 3.60 logs of protection, respectively), it induced lower levels in serum of specific IgG (with mixed IgG1/IgG2a) and IgA antibodies and, less IFN-ɣ and IL-4 than the subcutaneous route. No antibodies were detected in vaginal lavages or saliva. Fecal antigen-specific IgA was slightly higher in mice immunized with BLSOmp31/CpG-ODN/Coa-ASC16 subcutaneously compared with the ocular route. These results indicate that BLSOmp31/CpG-ODN/Coa-ASC16 was a safe and effective vaccine against B. ovis in mice. Highlights: BLSOmp31/CpG-ODN/Coa-ASC16 was administered by subcutaneous or ocular routes in BALB/c mice. This vaccine induced a mixed IgG2a/IgG1 profile and IFN-ɣ production in mice. This vaccine confers protection against B. ovis in mice. BLSOmp31/CpG-ODN/Coa-ASC16 is a novel vaccine candidate against B. ovis in sheep.